J. Gallo

发表

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

P. Ascierto, J. Larkin, A. Ribas, 2018, Pigment cell & melanoma research.

Abstract 3485: Inhibition of Notch signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells

P. Wei, Jennifer Yang, G. Han, 2012 .

Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers

W. Cheung, K. Thudium, E. Bouillaud, 2015, Clinical pharmacology : advances and applications.

Relationship between Pulmonary Adverse Events and Everolimus Exposure in Japanese and Non-Japanese Patients: A Meta-Analysis of Oncology Trials

A. Ravaud, S. Noguchi, A. Ohtsu, 2017, Oncology.

Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy

G. Hortobagyi, A. Ravaud, R. Motzer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-HumanStudyofPF-05212384 ( PKI-587 ) , a Small-Molecule , Intravenous , Dual Inhibitor of PI 3 K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015 .

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer

R. Sane, Dhruvitkumar S. Sutaria, D. Miles, 2022, Pharmaceutics.

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

J. Bono, C. Sternberg, M. Borre, 2021, The Lancet.

Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications

R. Sane, P. Agarwal, Dhruvitkumar S. Sutaria, 2022, Clinical and translational science.

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015, Clinical Cancer Research.

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

N. Curtin, R. Plummer, P. Lorigan, 2013, Cancer Chemotherapy and Pharmacology.

Selective down-regulation of integrin receptors in spheroids of squamous cell carcinoma.

R. Kramer, R. Sutherland, J. Gallo, 1994, Cancer research.

Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus

Michael P. Morrissey, A. R. Brannon, M. Riester, 2016, Cold Spring Harbor molecular case studies.

Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells.

K. Gajiwala, P. Wei, Jennifer Yang, 2013, Cancer letters.

Phase I clinical trial of gemcitabine (GEM) in combination with PF-00477736 (PF-736), a selective inhibitor of CHK1 kinase.

K. Wilner, G. Schwartz, C. Britten, 2010 .

Clinical predictors of response for coBRIM: A phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM).

P. Ascierto, J. Larkin, A. Ribas, 2016 .

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

G. Shapiro, J. Tabernero, E. Kwak, 2015, Clinical Cancer Research.

A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, F. D. De Braud, D. Geynisman, 2022, Journal of Clinical Oncology.

Abstract A177: Phase 1, dose-escalation, safety, pharmacokinetic and pharmacodynamic study of single agent PF-03758309, an oral PAK inhibitor, in patients with advanced solid tumors.

L. Mileshkin, L. Rosen, J. Goldman, 2011 .